### ðŸ«€ Cardiology: Supraventricular Tachycardia Management in Pregnancy

#### âœ… True Statements
1. In **hemodynamically stable pregnant patients** with symptomatic **supraventricular tachycardia (SVT)**, the firstâ€‘line therapy is **vagal maneuvers**, such as the **Valsalva maneuver** or **carotid sinus massage**.
2. When **SVT** persists after vagal maneuvers during pregnancy, **intravenous adenosine** is the **treatment of choice** to restore sinus rhythm.
3. **Adenosine** is **U.S.â€¯Food and Drug Administration (FDA) pregnancy categoryâ€¯C** but is considered the **safest acute antiarrhythmic** for SVT in pregnancy, with **no known teratogenic effects**.
4. **Atrioventricular nodal reentrant tachycardia (AVNRT)** is the most common mechanism of SVT during pregnancy and usually terminates with **adenosine**.
5. **Synchronized electrical cardioversion** should be reserved for **pregnant patients with SVT** who are **hemodynamically unstable** or refractory to vagal maneuvers, adenosine, and atrioventricularâ€‘nodeâ€“blocking drugs.
6. Maternal cardioversion in pregnancy requires **conscious sedation** with **obstetric team participation** and **continuous fetal monitoring**.
7. **Amiodarone** is **contraindicated** for the treatment of SVT in pregnancy because of **fetal toxicity** and limited efficacy for this arrhythmia.
8. **Î²â€‘Adrenergic blockers (Î²â€‘blockers)** such as **metoprolol** can be used to **prevent recurrent episodes** of SVT during pregnancy when needed after acute termination.
9. **Catheter ablation** may be considered during pregnancy for **recurrent or drugâ€‘refractory AVNRT** when symptoms remain significant despite medical therapy.

#### ðŸ’¬ Extra
1. Vagal maneuvers transiently increase vagal tone and slow atrioventricular nodal conduction, interrupting reâ€‘entrant circuits.
2. The **plasma halfâ€‘life** of adenosine is **<10â€¯seconds**, minimizing sustained fetal exposure.
3. Case reports of fetal adverse effects with adenosine have not been confirmed in larger series.
4. **AVNRT** involves dual atrioventricular nodal pathways forming a reâ€‘entry circuit dependent on nodal conduction.
5. Hemodynamic instability includes maternal hypotension, heart failure, chest pain, or altered mental status.
6. Fetal monitoring detects transient fetal bradycardia that can occur during maternal cardioversion.
7. **Amiodarone** crosses the placenta and has been associated with **fetal hypothyroidism** and **growth restriction**.
8. Î²â€‘Blocker prophylaxis is usually initiated with **cardioâ€‘selective agents** after assessing maternal blood pressure and fetal growth.
9. Modern ablation systems use **threeâ€‘dimensional electroâ€‘anatomic mapping** to minimize or eliminate fluoroscopic radiation.

#### ðŸ”· Tags
#Cardiology #EmergentCare #Pregnancy #SupraventricularTachycardia #AVNRT #Adenosine #CardioObstetrics

#### ðŸ“™ Reference
ParkÂ K, BaireyÂ MerzÂ CN, BelloÂ NA, etâ€¯al.; American College of Cardiology Cardiovascular Disease in Women Committee and the Cardioâ€‘Obstetrics Work Group. **Management of women with acquired cardiovascular disease from preâ€‘conception through pregnancy and postpartum: JACC Focus SeminarÂ 3/5.** *Journal of the American College of Cardiology.* 2021;77:1799â€‘1812. PMID:Â 33832606. doi:10.1016/j.jacc.2021.01.057

#### ðŸ†” Question ID
CVMCQ24048

#### ðŸ•’ Last Updated
FebruaryÂ 2025

---

#### ðŸ“– Related Text
MKSAPÂ 19: Cardiovascular MedicineÂ â€” Pregnancy and Cardiovascular Disease, Cardiovascular Medication Use During Pregnancy

---

### ðŸ“˜ Related Text Derivations

#### âœ… True Statements
1. Because **safety data are limited**, most **cardiovascular medications** are **not FDAâ€‘approved** for pregnancy and should be prescribed **only when the expected maternal benefit outweighs fetal risk** at the **lowest effective dose**.
2. **Î²â€‘Adrenergic blockers (Î²â€‘blockers)** cross the placenta and are present in human breast milk, so **fetal and newborn heartâ€‘rate monitoring** is recommended when they are used during pregnancy or lactation.
3. **Labetalol** is the **preferred Î²â€‘blocker** for **hypertension management** in pregnancy, whereas **metoprolol** is preferred when Î²â€‘blockade is needed for **heart failure** or **arrhythmia control**.
4. **Atenolol** is generally **avoided during pregnancy** because it has been linked to **premature delivery** and **smallâ€‘forâ€‘gestationalâ€‘age infants**.
5. **HMGâ€‘CoA reductase inhibitors (statins)** are **contraindicated** in pregnancy and should be **discontinued at least 6â€¯weeks (preferably 12â€¯weeks) before planned conception**.
6. **Sotalol** and **flecainide** have been used **safely** to prevent **recurrent tachyarrhythmias** during pregnancy when Î²â€‘blockers are inadequate or contraindicated.
7. The **LactMed database** provides comprehensive information on **medications and breastfeeding**, including potential adverse effects and safer therapeutic alternatives.
8. **Angiotensin-converting enzyme (ACE) inhibitors**â€”including **captopril, enalapril, and lisinopril**â€”are **contraindicated throughout pregnancy** because they are **teratogenic in the first trimester** and can cause **fetal or neonatal renal failure** when taken in the second or third trimester.
9. **Angiotensin receptor blockers (ARBs)** and **direct renin inhibitors** such as **aliskiren** are likewise **contraindicated in pregnancy** for the same risks of teratogenicity and fetal/neonatal kidney injury.
10. **Intravenous adenosine** has **no documented effect on fetal heart rate** when used to treat maternal supraventricular tachycardia during pregnancy.
11. **Low-dose aspirin (â‰¤ 81 mg/day)** is considered **safe for both pregnancy and breastfeeding**.
12. **Direct oral anticoagulants (DOACs)**â€”including **apixaban, dabigatran, rivaroxaban, edoxaban, and betrixaban**â€”carry **insufficient safety data**, so **pregnancy and lactation should be avoided** while receiving these agents.
13. The ultraâ€“short-acting Î²-blocker **esmolol** is a **second-line option** in pregnancy but produces **more pronounced fetal bradycardia** than other Î²-blockers.
14. **Diltiazem and verapamil** (non-dihydropyridine calcium-channel blockers) are **second-line agents** for maternal SVT; rapid intravenous administration can cause **maternal hypotension**, and they are occasionally used for **fetal SVT**.
15. **Sodium nitroprusside** is **contraindicated in pregnancy** owing to the risk of **fetal thiocyanate toxicity**.

#### ðŸ’¬ Extra
1. Dose minimization reduces fetal drug exposure while still achieving therapeutic goals.
2. Monitoring helps identify fetal bradycardia, a known effect of Î²â€‘blockade.
3. **Labetalol** has combined Î±â€‘ and Î²â€‘blocking properties that maintain uteroplacental blood flow.
4. Observational studies associated **atenolol** with impaired fetal growth when used early in pregnancy.
5. Cholesterol synthesis is critical for fetal development, underpinning statin contraindication.
6. Both agents have acceptable maternalâ€‘fetal safety profiles in published case series.
7. The **National Library of Medicine** maintains **LactMed** as a publicly accessible evidenceâ€‘based resource.
8. ACE-inhibitor exposure after organogenesis disrupts fetal renal blood flow, leading to oligohydramnios and pulmonary hypoplasia.
9. Like ACE inhibitors, ARBs impede the renin-angiotensin system; fetal effects mirror those seen with ACE-inhibitor exposure.
10. The supplemental table explicitly notes â€œNo change in fetal heart rateâ€ with adenosine.
11. Low-dose aspirin is widely used for pre-eclampsia prophylaxis and has no adverse lactation signal.
12. Registry data for DOACs are sparse; animal studies do not suggest teratogenicity, but human risk remains undetermined.
13. Esmololâ€™s rapid metabolism (tÂ½ â‰ˆ 9 min) permits tight titration but still crosses the placenta.
14. Maternal hypotension from rapid CCB infusion can compromise uteroplacental perfusion; slow bolus or oral dosing mitigates this risk.
15. Prolonged nitroprusside infusion generates cyanide and thiocyanate metabolites that readily cross the placenta.

#### ðŸ”· Tags
#Pregnancy #DrugSafety #CardioObstetrics #BetaBlocker #Statins #Lactation

---

### ðŸ“Š Supplemental Table

<!-- Safety of Drugs for Cardiac Disorders in Pregnancy and Lactation -->
<table>
  <caption><strong>Safety of Drugs for Cardiac Disorders in Pregnancy and Lactation</strong></caption>
  <thead>
    <tr>
      <th>Drug</th>
      <th>Use in Pregnancy</th>
      <th>Compatibility With Breastfeeding</th>
      <th>Comments</th>
    </tr>
  </thead>
  <tbody>
    <tr><th colspan="4" style="text-align:left;">ACE inhibitors</th></tr>
    <tr>
      <td>Captopril, enalapril</td>
      <td>No</td>
      <td>Yes</td>
      <td>Teratogenic in first trimester; cause fetal/neonatal kidney failure with second- or third-trimester exposure; scleroderma renal crisis is only indication</td>
    </tr>
    <tr>
      <td>Lisinopril</td>
      <td>No</td>
      <td>Unknown</td>
      <td>Same as above</td>
    </tr>
    <tr><th colspan="4" style="text-align:left;">Direct renin inhibitor</th></tr>
    <tr>
      <td>Aliskiren</td>
      <td>No</td>
      <td>Unknown</td>
      <td>Teratogenic in first trimester; causes fetal/neonatal kidney failure with second- or third-trimester exposure</td>
    </tr>
    <tr><th colspan="4" style="text-align:left;">Angiotensin receptor blockers (ARBs)</th></tr>
    <tr>
      <td>ARBs</td>
      <td>No</td>
      <td>Unknown</td>
      <td>Teratogenic in first trimester; cause fetal/neonatal kidney failure with second- or third-trimester exposure</td>
    </tr>
    <tr><th colspan="4" style="text-align:left;">Other antiarrhythmics</th></tr>
    <tr>
      <td>Adenosine</td>
      <td>Yes</td>
      <td>Unknown</td>
      <td>No change in fetal heart rate when used for supraventricular tachycardia</td>
    </tr>
    <tr>
      <td>Amiodarone</td>
      <td>No</td>
      <td>No</td>
      <td>Fetal hypothyroidism, prematurity</td>
    </tr>
    <tr><th colspan="4" style="text-align:left;">Antiplatelet and anticoagulant agents</th></tr>
    <tr>
      <td>Dipyridamole, clopidogrel</td>
      <td>Yes</td>
      <td>Unknown</td>
      <td>Second-line agent; no evidence of harm in animal clopidogrel studies; no human data</td>
    </tr>
    <tr>
      <td>Aspirin (&lt;81&nbsp;mg)</td>
      <td>Yes</td>
      <td>Yes</td>
      <td>&mdash;</td>
    </tr>
    <tr>
      <td>DOACs (apixaban, dabigatran, rivaroxaban, edoxaban, betrixaban)</td>
      <td>Unknown</td>
      <td>Unknown</td>
      <td>Pregnancy and lactation should be avoided in DOAC-treated patients; available data do not suggest a high risk for DOAC embryopathy or neonatal complications</td>
    </tr>
    <tr><th colspan="4" style="text-align:left;">Î²â€‘Blockers</th></tr>
    <tr>
      <td>Atenolol</td>
      <td>Yes</td>
      <td>No</td>
      <td>Second-line agent; low birth weight, intrauterine growth restriction</td>
    </tr>
    <tr>
      <td>Esmolol</td>
      <td>Yes</td>
      <td>Unknown</td>
      <td>Second-line agent; more pronounced bradycardia</td>
    </tr>
    <tr>
      <td>Labetalol</td>
      <td>Yes</td>
      <td>Yes</td>
      <td>Preferred drug in class</td>
    </tr>
    <tr>
      <td>Metoprolol</td>
      <td>Yes</td>
      <td>Yes</td>
      <td>Shortened half-life</td>
    </tr>
    <tr>
      <td>Propranolol</td>
      <td>Yes</td>
      <td>Yes</td>
      <td>Second-line agent; intrauterine growth restriction</td>
    </tr>
    <tr>
      <td>Sotalol</td>
      <td>Yes</td>
      <td>Unknown</td>
      <td>Second-line agent; insufficient data; reserve use for arrhythmia not responding to alternative agent</td>
    </tr>
    <tr><th colspan="4" style="text-align:left;">Calcium channel blockers</th></tr>
    <tr>
      <td>Diltiazem, verapamil</td>
      <td>Yes</td>
      <td>Yes</td>
      <td>Second-line agent; maternal hypotension with rapid intravenous infusion; used for fetal supraventricular tachycardia</td>
    </tr>
    <tr><th colspan="4" style="text-align:left;">Other cardiovascular drugs</th></tr>
    <tr>
      <td>Digoxin</td>
      <td>Yes</td>
      <td>Yes</td>
      <td>Second-line agent; shortened half-life</td>
    </tr>
    <tr>
      <td>Disopyramide</td>
      <td>Yes</td>
      <td>Yes</td>
      <td>Second-line agent; case reports of preterm labor</td>
    </tr>
    <tr>
      <td>Diuretics</td>
      <td>Yes</td>
      <td>Yes</td>
      <td>Second-line agent; use when needed for maternal volume overload only</td>
    </tr>
    <tr>
      <td>Flecainide</td>
      <td>Yes</td>
      <td>Unknown</td>
      <td>Second-line agent; inadequate data but used for fetal arrhythmia; case report of fetal hyperbilirubinemia</td>
    </tr>
    <tr>
      <td>Hydralazine</td>
      <td>Yes</td>
      <td>Yes</td>
      <td>Vasodilator of choice</td>
    </tr>
    <tr>
      <td>Lidocaine</td>
      <td>Yes</td>
      <td>Yes</td>
      <td>Treatment of choice for ventricular arrhythmias</td>
    </tr>
    <tr>
      <td>Sodium nitroprusside</td>
      <td>No</td>
      <td>No</td>
      <td>Potential fetal thiocyanate toxicity</td>
    </tr>
    <tr>
      <td>Organic nitrates</td>
      <td>Yes</td>
      <td>Unknown</td>
      <td>No apparent increased risk</td>
    </tr>
    <tr>
      <td>Phenytoin</td>
      <td>No</td>
      <td>Yes</td>
      <td>Known teratogenicity and bleeding risk; last resort for arrhythmia</td>
    </tr>
    <tr>
      <td>Procainamide</td>
      <td>Yes</td>
      <td>Yes</td>
      <td>Used for fetal arrhythmia</td>
    </tr>
    <tr>
      <td>Propafenone</td>
      <td>Yes</td>
      <td>Unknown</td>
      <td>Second-line agent; used for fetal arrhythmia</td>
    </tr>
    <tr>
      <td>Quinidine</td>
      <td>Yes</td>
      <td>Yes</td>
      <td>Preferred drug in class; increases digoxin levels</td>
    </tr>
  </tbody>
</table>

<p><em>ARB = angiotensin receptor blocker; DOAC = direct oral anticoagulant.</em></p>
<p><em>Adapted with permission from Roseneâ€‘Montella K, Keely EJ, Lee RV, etâ€¯al. Medical care of the pregnant patient. 2nd edition. Philadelphia, PA: American College of Physicians; 2008. ppÂ 356â€‘357. Â©2008 American College of Physicians.</em></p>
